The curative effects of Aspart 30 and Novolin 30R in treatment of type 2 diabetes were compared. Totally 128 patients with type 2 diabetes were selected and randomly divided into Aspart 30 (observation group) and Novolin 30R group (control group), 64 cases in each group. After treatment for continuous 12 wk, clin. efficacies of two groups were observed The biomarkers in both two groups after treatment determined at four time points were significantly lower than those before treatment, and the differences were statistically significant (P<0.05). The level of postprandial 2-h plasma glucose (2 h-PG) in observation group was lower than those in control group, and the difference was statistically significant (P<0.05). The insulin amount, incidence of hypoglycemia and hypoglycemia cases were lower in observation group than in control group, and the differences were statistically significant (P<0.05). After treatment, the level of glycosylated Hb (HbA1c) was significantly decreased, which was lower in observation group than in control group and observation group patients, and the difference was statistically significant (P<0.05). Aspart 30 and Novolin 30R show good curative effects in treatment of type 2 diabetes, and Aspart 30 has better curative and stable effect, especially on postprandial 2 h-PG, with reduced dosage of insulin, cases and incidence of hypoglycemia, which is worthy of clin. popularization and application.